Timing of Steroid Initiation and Response Rates to Immune Checkpoint Inhibitors in Metastatic Cancer

Diana V. Maslov, Ochsner Medical Center - New Orleans
Karine Tawagi, Ochsner Medical Center - New Orleans
Madhav Kc, LSU Health Sciences Center- New Orleans
Victoria Simenson, Ochsner Medical Center - New Orleans
Helen Yuan, Ochsner Medical Center - New Orleans
Cameron Parent, Ochsner Medical Center - New Orleans
Adi Bamnolker, Ochsner Medical Center - New Orleans
Richa Goel, Ochsner Medical Center - New Orleans
Zoe Blake, The University of Queensland
Marc R. Matrana, Ochsner Cancer Institute
Daniel H. Johnson, Ochsner Cancer Institute


Background Corticosteroids (CS) are the mainstay of immune-related adverse effect (irAE) management, as well as for other indications in cancer treatment. Previous studies evaluating whether CS affect immune checkpoint inhibitor (CPI) efficacy compared patients receiving CS versus no CS. However, there is a paucity of clinical data evaluating the timing of concomitant CS and CPI efficacy. Methods We retrospectively collected data from patients who received CS during CPI treatment at a single institution. Patients were in two cohorts based on timing of initiation of CS (≥2 months vs <2 months after initiating>CPI). Patient characteristics, irAEs, cancer type, treatment type, treatment response/progression per RECIST V.1.1, and survival data were collected. Kaplan-Meier and Cox proportional hazard regression methods estimated HRs for the primary endpoint of progression-free survival (PFS) along with overall survival (OS). Results We identified 247 patients with metastatic cancer who received CS concurrently with CPIs. The median time on CS was 1.8 months. After adjusting for treatment type, tumor type, brain metastases, and irAEs, those treated with CS ≥2 months after starting CPI had a statistically significant longer PFS (HR=0.30, p<0.001), and OS (HR 0.34, p<0.0001) than those who received CS <2 months after starting CPI. Objective response rate (ORR) for patients on CS ≥2 months was 39.8%, versus ORR for patients <2 months was 14.7% (p value =<0.001) Conclusion Our results suggest that early use of CS during CPI treatment significantly hinders CPI efficacy. This data needs to be validated prospectively. Future studies should focus on the immune mechanisms by which CSs affect T-cell function early in the CPI treatment course.